Amphastar Pharmaceuticals, Inc.
AMPHAmphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Drugs in Pipeline
15
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Epinephrine HFA-MDI (E004)
Asthma
E004 (Epinephrine Inhalation Aerosol) HFA-MDI
Asthma
Primatene Mist
Asthma
Epinephrine inhalation
Asthma
NovoLog
Pharmacokinetics
I004
Pharmacokinetics
Epinephrine inhalation aerosol
Asthma
albuterol inhalation powder
Asthma
Albuterol DPI 25 mcg/inh
Asthma
A006 DPI
Asthma
Epinephrine Inhalation Aerosol, HFA
Asthma
Proventil® MDI
Asthma
A006
Asthma
Arm T1: Primatene Mist HFA
Asthma
Hyaluronidase
Allergic Skin Reaction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epinephrine HFA-MDI (E004) | Phase 3 | Asthma | - | - |
E004 (Epinephrine Inhalation Aerosol) HFA-MDI | Phase 3 | Asthma | - | - |
Primatene Mist | Phase 3 | Asthma | - | - |
Epinephrine inhalation | Phase 3 | Asthma | - | - |
NovoLog | Phase 3 | Pharmacokinetics | - | - |
I004 | Phase 3 | Pharmacokinetics | - | - |
Epinephrine inhalation aerosol | Phase 3 | Asthma | - | - |
albuterol inhalation powder | Phase 2 | Asthma | - | - |
Albuterol DPI 25 mcg/inh | Phase 2 | Asthma | - | - |
A006 DPI | Phase 2 | Asthma | - | - |
Epinephrine Inhalation Aerosol, HFA | Phase 2 | Asthma | - | - |
Proventil® MDI | Phase 2 | Asthma | - | - |
A006 | Phase 2 | Asthma | - | - |
Arm T1: Primatene Mist HFA | Phase 2 | Asthma | - | - |
Hyaluronidase | Phase 2 | Allergic Skin Reaction | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amphastar Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in Amphastar Pharmaceuticals, Inc.'s (AMPH) pipeline across Phase 3, Phase 2. Its lead program is Epinephrine HFA-MDI (E004) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amphastar Pharmaceuticals, Inc.'s next FDA catalyst?→
Amphastar Pharmaceuticals, Inc.'s (AMPH) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMPH biotech catalysts?→
Add AMPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amphastar Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.